The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...

The 1) Market is expected to reach a substantial USD 34.83 billion by 2033, according to a new report. This reflects a ...

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

HIV therapy protects the immune system by controlling the virus and preventing disease progression. This article takes a ...

Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...

The company is also developing a vaccine against a bacteria that causes urinary tract infections, bloodstream infections, and pneumonias, and testing approved drugs Cabenuva and Edurant in ...

The list includes dengue fever, chikungunya, leptospirosis and Valley fever, says University of Washington professor Peter ...

IJ Anosike, M.D., M.P.H., assistant professor of pediatrics at the Montefiore Medical Center in the Bronx, explains how COVID ...

GILD's recent upbeat data on lenacapavir underscore the investigational drug???s potential to prevent HIV in the targeted ...

New data to be shared on GSK’s RSV vaccine across different age groups of patients at increased risk • Efficacy data for gepotidacin in ...